Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darigabat in Participants With Panic Disorder
NCT05941442Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in panic disorder comparing Darigabat with Placebo (2 arms). Primary endpoint: Percentage of Participants Free of Panic Attacks. Started Jul 2023; status: terminated.
02
Drugs
darigabat
03
Conditions
panic disorder
Beyond the preview
Go deeper on NCT05941442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941442.